Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Fresenius Medical Care North America | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Studies have shown that end stage renal disease (ESRD) patients have higher levels of blood markers which their body makes in response to increased stress and injury. An increase in these markers have been shown to be related to cardiovascular disease and death in ESRD patients. This study will examine whether antioxidant therapy (Vitamin E and alpha lipoic acid) may decrease these markers.
Oxidative stress and acute phase inflammation are now recognized to be highly prevalent in the hemodialysis population, and several lines of evidence point to their contribution in atherosclerosis development. Biomarkers of the inflammatory state such as C-reactive protein (CRP) and interleukin-6 are robust predictors of cardiovascular events and mortality in the dialysis population. The uremic state is characterized by retention of oxidized solutes including reactive aldehyde groups and oxidized thiol groups. It has recently been demonstrated that initiation of maintenance hemodialysis does not improve biomarkers of oxidative stress or inflammation, suggesting that dialysis alone is inadequate to control the atherosclerotic uremic metabolic state. In this study we hypothesize that administration of antioxidant therapy will decrease biomarkers of acute phase inflammation and oxidative stress while improving the erythropoietic response in hemodialysis patients.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ALA and Vitamin E | Active Comparator | 600 mg (2 pills 300 mg each) of alpha lipoic acid (ALA) and 666 IU (1 pill) of alpha, gamma, beta and delta (mixed) tocopherols (Vitamin E) taken orally on a daily basis for 6 months |
|
| Placebo | Placebo Comparator | placebo for ALA (2 pills) and for Vitamin E (1 pill) taken orally on a daily basis for 6 months |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Alpha, gamma, beta, and delta (mixed) tocopherols | Drug | approximately 666 IU daily (1 pill) for 6 months |
|
| Measure | Description | Time Frame |
|---|---|---|
| F2-isoprostane (F2-iso) | F2-iso is a sensitive laboratory assay for serum levels of F2-isoprostane, which is a biomarker of oxidative stress. | month 6 |
| Measure | Description | Time Frame |
|---|---|---|
| Interleukin-6 (IL-6) | IL-6 is a sensitive laboratory assay for serum levels of interleukin-6, which is a pro-inflammatory cytokine used to evaluate the inflammatory response. | month 6 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jonathan Himmelfarb, MD | MaineHealth | Principal Investigator |
| Alp Ikizler, MD | Vanderbilt University Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Fresenius Medical Care North America | Nashville | Tennessee | 37215 | United States |
There is a 1-month period between enrollment and assignment to a treatment group. Although 385 subjects were enrolled, only 356 were randomized (29 subjects withdrew consent prior to randomization). Also, 31 subjects were administratively withdrawn (due to widespread protocol non-compliance at one site) leaving 325 subjects assigned to a group.
This study was conducted at the Vanderbilt University Medical Center and at Fresenius Medical Care North America Dialysis clinics between April 2006 and September 2010.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | ALA and Vitamin E | 600 mg (2 pills 300 mg each) of alpha lipoic acid (ALA) and 666 IU (1 pill) of mixed (alpha, gamma, beta and delta) tocopherols (Vitamin E) taken orally on a daily basis for 6 months |
| FG001 | Placebo | placebo for ALA (2 pills) and for Vitamin E (1 pill) taken orally on a daily basis for 6 months |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | ALA and Vitamin E | 600 mg (2 pills 300 mg each) of alpha lipoic acid (ALA) and 666 IU (1 pill) of mixed (alpha, gamma, beta and delta) tocopherols (Vitamin E) taken orally on a daily basis for 6 months |
| BG001 | Placebo |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | F2-isoprostane (F2-iso) | F2-iso is a sensitive laboratory assay for serum levels of F2-isoprostane, which is a biomarker of oxidative stress. | The number of participants for analysis was based on those subjects who completed the 6-month study. Note that 8 subjects were excluded due to samples being lost. The analysis was per protocol. | Posted | Mean | Standard Deviation | ng/ml | month 6 |
|
6 months
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | ALA and Vitamin E | 600 mg (2 pills 300 mg each) of alpha lipoic acid (ALA) and 666 IU (1 pill) of mixed (alpha, gamma, beta and delta) tocopherols (Vitamin E) taken orally on a daily basis for 6 months |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| cardiac | Cardiac disorders | Non-systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| GI upset | Gastrointestinal disorders | Non-systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| T. Alp Ikizler, MD | Vanderbilt University | alp.ikizler@vanderbilt.edu |
Not provided
| ID | Term |
|---|---|
| D007676 | Kidney Failure, Chronic |
| ID | Term |
|---|---|
| D051436 | Renal Insufficiency, Chronic |
| D051437 | Renal Insufficiency |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D005720 | Gamma Rays |
| D050986 | YY1 Transcription Factor |
| D024505 | Tocopherols |
| D014810 | Vitamin E |
| D008063 | Thioctic Acid |
| ID | Term |
|---|---|
| D060733 | Electromagnetic Radiation |
| D055590 | Electromagnetic Phenomena |
| D060328 | Magnetic Phenomena |
| D055585 | Physical Phenomena |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Alpha lipoic acid | Drug | 600 mg daily (2 pills 300 mg each) for 6 months |
|
| Placebo | Drug | placebo for alpha, gamma, beta, and delta (mixed) tocopherols; 1 pill daily for 6 months |
|
| Placebo | Drug | placebo for alpha lipoic acid; 2 pills daily for 6 months |
|
placebo for ALA (2 pills) and for Vitamin E (1 pill) taken orally on a daily basis for 6 months
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
|
|
|
| Secondary | Interleukin-6 (IL-6) | IL-6 is a sensitive laboratory assay for serum levels of interleukin-6, which is a pro-inflammatory cytokine used to evaluate the inflammatory response. | The number of participants for analysis was based on those subjects who completed the 6-month study. Note that 8 subjects were excluded due to samples being lost. The analysis was per protocol. | Posted | Mean | Standard Deviation | pg/ml | month 6 |
|
|
|
|
| 44 |
| 160 |
| 91 |
| 160 |
| EG001 | Placebo | placebo for ALA (2 pills) and for Vitamin E (1 pill) taken orally on a daily basis for 6 months | 52 | 165 | 85 | 165 |
| infection | Infections and infestations | Non-systematic Assessment |
|
| pulmonary | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
|
| GI upset | Gastrointestinal disorders | Non-systematic Assessment |
|
| access related | Vascular disorders | Non-systematic Assessment | Any adverse event related to the dialysis access (catheter, graft, or fistula). |
|
| fluid overload | Cardiac disorders | Non-systematic Assessment |
|
| diabetes | Endocrine disorders | Non-systematic Assessment |
|
| edema | Renal and urinary disorders | Non-systematic Assessment |
|
| hypertension/hypotension | Vascular disorders | Non-systematic Assessment |
|
| neurological | Nervous system disorders | Non-systematic Assessment |
|
| viral infection | Infections and infestations | Non-systematic Assessment |
|
| anemia | Blood and lymphatic system disorders | Non-systematic Assessment |
|
| electrolyte disorder | Metabolism and nutrition disorders | Non-systematic Assessment |
|
| musculoskeletal | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
|
| pain | General disorders | Non-systematic Assessment |
|
| dizziness | General disorders | Non-systematic Assessment |
|
| lesions | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
|
| trauma | General disorders | Non-systematic Assessment |
|
| other | General disorders | Non-systematic Assessment |
|
| infection | Infections and infestations | Non-systematic Assessment |
|
| access related | Vascular disorders | Non-systematic Assessment | Any adverse event related to the dialysis access (catheter, graft, or fistula). |
|
| pain | General disorders | Non-systematic Assessment |
|
| viral infection | Infections and infestations | Non-systematic Assessment |
|
| pulmonary | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
|
| cardiac | Cardiac disorders | Non-systematic Assessment |
|
Not provided
Not provided
Not provided
| D052776 |
| Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D011827 | Radiation |
| D011839 | Radiation, Ionizing |
| D050981 | Erythroid-Specific DNA-Binding Factors |
| D004268 | DNA-Binding Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D014157 | Transcription Factors |
| D001578 | Benzopyrans |
| D011714 | Pyrans |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
| D013876 | Thiophenes |
| D013457 | Sulfur Compounds |
| D003067 | Coenzymes |
| D045762 | Enzymes and Coenzymes |
| D005227 | Fatty Acids |
| D008055 | Lipids |